NCT03883542Active, not recruiting
Sub-type Specific Genomic Mutations in sBOTs
Sub-type Specific Genomic Mutations in Serous Borderline Ovarian Tumors
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The aim of this study is to identify different origin in carcinogenesis between serous borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c. with invasive implants and d. with micropapillary pattern. The presence of specific mutations could suggest for a more aggressive primary treatment if a higher risk of recurrence can be expected.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 20 (actual)
- First submitted
- 26 Feb 2019
- Start date
- Jan 2017
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Diseases
- Ovarian cancer
- NCT number
- NCT03883542
What you commit to
- Study type: Observational
- Participants enrolled: 20
- From Jan 2017 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Presence of invasive ovarian carcinoma.
Who the study is looking for
- Paraffin embedded material from the original borderline ovarian tumor must be present and of good quality for DNA extraction.
- Original slides are available for central pathological review.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis UZBrussel Coordinator of this site? Confirm its status | Jette | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.